Phenomenex has brought out a Chiral Screening Service for customers in pharmaceutical and natural products research and development.
This service provides target screening using a library of HPLC and SFC columns, including the Phenomenex Lux polysaccharide-based offerings, which demonstrate a success rate approaching 90 per cent.
After resolving the chiral compound, Phenomenex also produces method development and optimisation for the service customer, all within 10 business days.
Enantiomers of chiral compounds may have different pharmacological effects in biological systems.
Regulations require that enantiomers of all chiral drugs in development be screened separately on their pharmacodynamic and pharmacokinetic properties.
The Phenomenex team of chiral experts will customise a plan for each screening project, taking into account specific requirements and overall separation goals.
Once a project is completed, the customer will receive a report that details the optimal method, including information on the chiral stationary phase (CSP) selected for the separation, running conditions and associated chromatograms.
